Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

Shuai Li,Xin-Yang Li,Ting-Jian Zhang,Ju Zhu,Kai-Li Liu,De-Pu Wang,Fan-Hao Meng,Xin-yang Li,Ting-jian Zhang,Kai-li Liu,De-pu Wang,Fan-hao Meng
DOI: https://doi.org/10.1016/j.bioorg.2021.104840
IF: 5.307
2021-06-01
Bioorganic Chemistry
Abstract:<p>To further explore the research of novel PARP-1 inhibitors, we designed and synthesized a series of novel amide PARP-1 inhibitors based on our previous research. Most compounds displayed certain antitumor activities against four tumor cell lines (A549, HepG2, HCT-116, and MCF-7). Specifically, the candidate compound <strong>R8e</strong> possessed strong anti-proliferative potency toward A549 cells with the IC<sub>50</sub> value of 2.01 μM. Compound <strong>R8e</strong> had low toxicity to lung cancer cell line. And the in vitro enzyme inhibitory activity of compound <strong>R8e</strong> was better than rucaparib. Molecular docking studies provided a rational binding model of compound <strong>R8e</strong> in complex with rucaparib. The following cell cycle and apoptosis assays revealed that compound <strong>R8e</strong> could arrest cell cycle in the S phase and induce cell apoptosis. Western blot analysis further showed that compound <strong>R8e</strong> could effectively inhibit the PAR's biosynthesis and was more effective than rucaparib. Overall, based on the biological activity evaluation, compound <strong>R8e</strong> could be a potential lead compound for further developing novel amide PARP-1 inhibitors.</p>
biochemistry & molecular biology,chemistry, organic
What problem does this paper attempt to address?